• The 2018 U.S. Farm Bill removed “hemp” from the definition of cannabis but did not allow for inclusion of cannabidiol (“CBD”) in food or supplements
• Regulations will remain in terms of labeling and serving size, and they will be determined by CDPH (California Department of Public Health)
• Green Hygienics exclusively works with industrial hemp and stands to benefit from the signing of AB45 in California

The Farm Bill of 2018 was a game-changer in the hemp industry. Signed into law in December 2018, the Farm Bill removed “hemp” (Cannabis sativa L) and its derivatives comprised of a low concentration (less than 0.3%) of the psychoactive 9-tetrahydrocannabinol (“THC”) compound from the Controlled Substances Act definition of cannabis. Within the bill, the FDA preserved authoritative rights over hemp products (https://ibn.fm/5Zy7w). Therefore, all hemp products must meet any applicable FDA requirements or standards – much like any other product sold legally on the market. Assembly Bill 45 and Its Provisions Recently, more than three years after this ruling, Assembly Bill 45 (AB45) was signed by Governor Gavin Newsome, allowing for hemp-derived cannabinoids, extracts, and derivatives, in food and dietary supplements. However, AB45 does not come without restrictions (https://ibn.fm/wQL1d). The legislation comes only weeks after the FDA denied two New Dietary Ingredient applications filed by well-known CBD brands. There is currently no guidance for the serving size, which CDPH will address. Key provisions of the bill include:

• The food, drink, supplement, etc., is not adulterated by including industrial hemp or its derived cannabinoids, derivatives, or extracts. Manufacturers must register with theCDPH, demonstrate the proper industrial hemp sourcing, and comply with good manufacturing practices. Industrial hemp may not be included in any product that contains alcohol, tobacco, or nicotine.
• The use of any cannabinoid known to exhibit intoxicating properties is prohibited. For example, under AB45, THC – including delta 9 and delta 8 derivatives – is strictly prohibited. The CDPH will have full discretion to include or exclude within the definition of any other cannabinoid (except CBD) that has been determined to cause intoxication.
• AB45 only focuses on the final extract, which cannot exceed 0.3% THC concentration – not acknowledging the Interim Final Rule of the Drug Enforcement Administration (“DEA”) to classify any hemp extraction that exceeds the 0.3% rule as a Schedule 1 controlled substance.
• Inhalable products within the state lines are prohibited until the new tax on inhalable products is authorized.
• Hemp manufacturers must undergo rigorous testing requirements – including that the hemp must be tested by an independent third-party testing laboratory in raw extract final form. Testing requirements for contamination levels will be the same as the ones used for cannabis.
• AB45 prohibits labeling, advertising, and marketing any hemp product using a “health-related statement.” The packaging and labeling must include:
• A label, barcode, and an internet website or QR code that links to the certificate of analysis containing the product name, contact information, batch number, the concentration of cannabinoids, and the contaminant levels
• An expiration or “best by” date, if applicable
• A statement that indicates the product should be avoided by children, pregnant, or breastfeeding mothers unless discussed with a medical professional
• A statement that all cannabinoid products should be kept out of the reach of children
• The statement: THE FDA HAS NOT EVALUATED THIS PRODUCT FOR SAFETY OR EFFICACY

Companies that only grow and produce industrial hemp stand to benefit from Governor Newsome signing AB45. With a focus on the high standard cultivation and processing of industrial hemp, California-based Green Hygienics Holdings (OTCQB: GRYN) is one company expected to benefit from the new bill. The company grows its hemp in a controlled environment at its farm in California, which, with 824 acres and 392,000 square feet of greenhouse space, is the largest USDA Certified Organic hemp for CBD farm in North America. The company will soon manufacture pharmaceutical-grade bioactive cannabinoids and other active ingredients that can be used for multiple applications in various sectors such as the pharmaceutical, nutraceutical and skincare industries. Green Hygienics is registered with the FDA and was granted USDA Organic Certification in 2020. Products available from the company are currently found in the US, and will be in international markets soon. For more information, visit the company’s website at www.GreenHygienics.com. NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

In Tuesday morning trading, the ProShares Bitcoin Strategy ETF (NYSE: BITO) made its debut, marking a monumental occasion in the developing story of cryptocurrency regulation. The fund, which tracks CME bitcoin futures, or contracts speculating on the future prices of bitcoin, rose by roughly 3% early in the session and continues to hold those gains at time of publishing. The crypto sector as a whole has pursued a bitcoin-focused ETF for years now, with asset managers submitting proposals for spot bitcoin ETFs as early as 2017. To date, however, the U.S. Securities and Exchange Commission had consistently rejected these proposals, maintaining the stance that none of the applications were able to prove market resistance to manipulation. While the ProShares Bitcoin Strategy ETF falls short of the spot bitcoin ETF that many in the industry hope is on the horizon, experts agree that Tuesday’s opening stands as a turning point in the regulatory approach of the SEC. “Remember, there’s a difference between the cash ETF, obviously, and the ETF that everybody’s talking about right now. I have a preference for the cash ETF, but I love the fact that the SEC is allowing for the futures ETF,” Anthony Scaramucci, founder and managing partner of SkyBridge Capital, told CryptoCurrencyWire in an exclusive. “It’s just a sign that they’ve decided that they know the blockchain is going to be a very big component of the future of the financial services industry. I take this as a monumental decision…to allow the United States to stay the leader in financial services globally. I think it’s a very positive sign.” To stay up to date on the latest cryptocurrency news, signup for the CryptoCurrencyWire newsletter at www.CryptoCurrencyWire.com and for more on SkyBridge Capital & First Trust Skybridge Bitcoin Fund L.P. visit www.SkyBridgeBitcoin.com.

The USA CBD Expo Chicago aims to be the greatest and largest CBD/hemp event in the country, bringing the most creative and best goods and brands to businesses and consumers on a constant basis, and compressing a rapidly growing industry into one all-encompassing, top event. This event is geared toward both newbies to the CBD sector and seasoned veterans. The conference will feature some of the industry’s top experts, who will deliver a variety of instructional seminars, keynote talks, and workshops to attendees. The seminars will focus on the commercial side of the CBD and hemp industries, as well as current and future CBD market trends, health advantages, ongoing legalization initiatives, and medicinal use cases. CBD for sexual wellbeing, psychedelics education, the potency of medicinal mushroom extracts, and information about delta-8 and its legality are among the topics to be discussed. Why Attend the Expo? The windy city has a population of about 10 million people and receives over 58 million visitors each year. Many of them are attracted by the recent legalization of recreational cannabis, which has seen monthly retail sales of the substance surge to an estimated $40 million in income. You have an opportunity to attend the expo and educate yourself on the various aspects of the cannabis industry and how you could step in it. Seminars educating people on the various resources and methodologies about the wonder plant can help you as well! Key Convention Aspects:

• The USA CBD Expo, which is part of the country’s largest CBD event series, will cater to CBD industry novices as well as seasoned industry professionals.
• A series of keynote presentations and conversations will be offered by some of the industry’s greatest thinkers and innovators during the conference.
• The Expo will include over 500 of the industry’s largest and most innovative brands, all of which will present their different product lines under one roof.

The USA CBD Expo will feature a wide range of industry thought leaders, including Angela Ardolino of CBD Dog Health, Asa Waldstein of the Supplement Advisory Group, Angela Boyce of Primo Gardens, Jody McGinness of the Hemp Industries Association, and Jason Gann, star of Wilfred and representing Wilfred CBD, among a variety of other featured speakers. To know more about this event, visit https://usacbdexpo.com/chicago/.

• License prequalification should give HENC shareholders great confidence in strategic Michigan business plan
• Hero Technologies, Blackbox now beginning the last step in process of obtaining licensing approval
• Once full funding has been reached, BlackBox anticipates being shovel ready within two months

In its ongoing commitment to position itself as a multistate operator in the cannabis sector, Hero Technologies (OTC: HENC) is focused on becoming fully licensed in Michigan. As part of that process, the company recently announced that Blackbox Systems and Technologies LLC, a HENC subsidiary, has fulfilled the requirements for step 1 prequalification approval for a Class C Medicinal Use cannabis license in Michigan; Blackbox also received step 1 prequalification approval for a Class C Adult-Use cannabis license (https://ibn.fm/x5UjK). “Michigan’s two-step marijuana licensing process is one of the toughest in the country, and passing the scrutiny of state regulators for license prequalification should give our shareholders great confidence in our Michigan business plan,” said Hero Technologies CEO Gina Serkasevich. “The state of Michigan is also one of the fastest-growing cannabis markets in the nation, with monthly sales approaching $150 million in only the second year of legal operations, so our shareholders should also be excited about our near-term prospects for rapid growth.” In order to obtain step 1 prequalification approval, companies must provide detailed information to the Michigan Marijuana Regulatory Agency (“MRA”) regarding sources of capitalization, corporate officers, directors, major shareholders, insurance compliance, and financial statements attested to by a certified public accountant; submitting companies and key officials must also undergo extensive background checks. HENC went to great lengths to meet the requirements and provide all the information required in order to obtain the prequalification approvals for both licenses. With those approvals in hand, Hero Technologies and Blackbox are now beginning the next — and last — step in the process of obtaining licensing approval in Michigan: establishment use or full license approval for a newly constructed medical marijuana facility. Completion of this second step will allow HENC to move forward with its plans for cultivation of cannabis in Michigan. Looking ahead, the company has already obtained approval from the township of Pulaski for three class C medicinal use cannabis licenses dependent on completion of step 2 and MRA approval. That approval came after HENC provided Pulaski officials with detailed information regarding the proposed facility site as well as construction documents, a business plan, security arrangements, a sanitation plan and revenue projections. The company has noted that final approval and licensing for both medicinal and adult-use licenses will come after the greenhouse have been completed, including obtaining a certificate of occupancy and the final MRA inspection. With costs for the Michigan project estimated to reach $8.94 million, the company is working to raise the funds. Once full funding has been reached, BlackBox anticipates being shovel ready within two months. In addition to its Michigan expansion plans, Hero Technologies is undertaking expansion in Colorado through its wholly owned subsidiary Mile High Green LLC. The company’s strategic business plan includes cannabis genetic engineering, space for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multistate operator. HENC is also planning to expand in Massachusetts through its wholly owned subsidiary MassCannabis LLC. In addition, Hero Technologies owns and operates two hemp websites: HighlyRelaxing.com under Highly Relaxing LLC and VeteranHempCo.com. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• Avricore, through its HealthTab(TM) flagship offering, is bringing health diagnosis and treatment closer to people
• The point-of-care testing market, which Avricore is part of, shows incredible potential for growth in the coming years
• Strategic investments and critical partnerships with other key players in the industry have allowed Avricore to stand out among its competitors
• This has also enabled the company to create value for stakeholders and better outcomes for patients

The point-of-care testing market is projected to be valued at $50.6 billion by 2025, up from $29.5 billion in 2020. This will represent a compounded annual growth rate (“CAGR”) of 11.4% during the forecast period, mainly fueled by the rising cases of infectious diseases, technological advancements of point-of-care devices, along with an increase in investments by key companies and players in the industry (https://ibn.fm/qn479). One such player is Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a company at the forefront of moving pharmacy forward. Described as a heath diagnostics technology innovator focused on acquiring and developing early-stage technologies, Avricore has been at the frontage of offering a turnkey point-of-care testing platform that, so far, has created value for stakeholders and better outcomes for its patients. Through HealthTab(TM), Avricore’s flagship offering, the company has effectively turned pharmacies into community diagnostic centers, bringing health diagnosis and treatment even closer to the people. With this platform, pharmacies take on a more significant role in primary health services, ultimately improving the quality of life for patients living with chronic illnesses. Avricore understands that partnering with pharmacies is ideal if at all the point-of-care model is to work effectively. In the United States (“U.S.”), the United Kingdom (“U.K.”), and Canada, there are over 110,000 pharmacy locations. Each of them can be equipped with Avricore’s three rapid testing devices, allowing patients to easily and quickly diagnose anything from their kidney functions to Covid-19 (https://ibn.fm/9yf4S). For instance, in North America alone, it is projected that over 102 million people will be dealing with diabetes or prediabetes by 2030. Having point-of-care facilities close by, mainly in their closest pharmacies, will allow them to quickly diagnose their conditions and manage them properly before it is too late. Having partnered with other key industry players such as Abbott Rapid Diagnostics and Shoppers Drug Mart, Avricore has secured the integral equipment necessary for patient point-of-care testing and locations that bring the equipment even closer to the target patients. By doing so, it is, ultimately, driving better outcomes for them. Additionally, it has brought on board companies that believe in the future of point-of-care testing and share in Avricore’s vision. “We’re proud to be part of this amazing journey with HealthTab as we believe point-of-care testing in pharmacies is the future,” noted Daniel Saint-Pierre, the General manager of Abbott Rapid Diagnostics. Mohammed Adel Elsabakhawi, a Pharmacist and Associate Owner of Shoppers Drug Mart, also noted, “I’m so excited to have HealthTab in my store because I believe it demonstrates a new and better way to do pharmacy practice.” Avricore has three main testing instruments- Afinion 2(TM), I-Stat, and ID Now. Afinion 2 is beneficial for heart disease screening and diabetes diagnosis, while I-Stat tests kidney function and electrolytes. ID Now, Avricore’s most recent addition, is used to test Influenza A and B, Strep and Covid-19. So far, the company has tested and developed its technology and is in the commercialization stage, intending to expand into more pharmacies in Canada and around the world (https://ibn.fm/6LRbL). Avricore’s ultimate goal is to become the leading provider of point-of-care testing in pharmacy and real-world evidence studies, and its achievements so far place it on track to achieving this goal. The company projects that by October 2023, it will have its instruments in about 600 different locations, with estimated revenues surpassing $800,000. It also projects that Canada will play host to the majority of the pharmacies, followed by the U.S. and the U.K. With its revenue model broken into equipment leasing, consumables, screening tests, data, and API integration, Avricore demonstrates its commitment to offering value-added patient services and creating value to its shareholders. Even with the success achieved so far, the company is still pushing the envelope, innovating with its technology and forging healthy relationships that allow it to move even closer to achieving this specific goal. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
• The company recently announced the beta launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores
• US diabetes-related healthcare expenditures totalled $760 billion in 2019 alone, equating to an annual spend of over $9,000 per diabetic patient

Nemaura Medical (NASDAQ: NMRD) is a cutting-edge medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company recently carried out the beta launch of MiBoKo, a new proprietary metabolic health program designed to utilize a non-invasive glucose sensor and an AI based mobile application (https://ibn.fm/FsV8g). MiBoKo, an addition to Nemaura Medical’s diabetes-focused product portfolio, has been in development for the past 18 months and seeks to address a significant and growing mass-market opportunity which the company believes could benefit roughly a third to half of the global population. The MiBoKo application uses a non-invasive glucose sensor to measure and monitor the user’s metabolic health scores based on glucose tolerance or insulin resistance. Prediabetic patients or those facing obesity concerns or looking to monitor their glucose intake would benefit from using the application. Nemaura Medical’s cutting-edge health tracking program uses a wearable sensor and mobile app that provides users with personalized information by tracking their metabolism when used in conjunction with one another. For example, users can draw insights into how their bodies process sugar by tracking their metabolic health score. This figure provides a holistic overview of the impact of an individual’s daily nutrition on their health. Dr. Faz Chowdhury, Nemaura’s Chief Executive Officer, commented in regard to MiBoKo’s launch, “A person’s response to sugar intake can influence a number of factors from appetite and body weight to sleep patterns, energy levels, and even mood, not to mention also being a considerable factor in chronic diseases like diabetes, heart disease, and dementia.” Chowdhury continued, “With MiBoKo, we are able to extend our proprietary non-invasive device and sensor technology and interactive lifestyle and AI coaching programs beyond the traditional diabetes market and into an adjacent, yet separate, market application of metabolic health.” In addition to receiving real-time updates on their metabolic health scores, MiBoKo users will be eligible to receive weekly and monthly reports illustrating the changes in their metabolic health scores as well as providing a breakdown of how individual habits were impacting their overall health and wellbeing. The MiBoKo application will also suggest how to amend daily routines (i.e., eating more or less of a particular food or exercising during peak energy levels), providing MiBoKo users with granular and actionable intelligence on how to transform their health for the better. Over 420 million people globally are currently living with diabetes, with prediabetic cases totalling almost three times that number. Through their flagship product, the sugarBEAT(R), a wearable and non-invasive continuous glucose monitor, and now, the MiBoKo application, Nemaura Medical have sought to improve the health prospects for an ever-increasing proportion of the global population, with US diabetes-related health care expenditures totalling over $760 billion in 2019 alone (https://ibn.fm/88DpX). For more information, visit the company’s websites at www.NemauraMedical.com or www.MiBoKo.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• Infobird, a leading software-as-a-service (SaaS) provider of AI powered customer engagement solutions in China, is one of the few companies in China that has built a customer engagement SaaS on a cloud-native architecture, and has remained consistent with innovation and offering unique customer engagement solutions
• The company’s products and services ride on the backbone of their self-developed, cloud-computing structure, robotic-process-automation (“RPA”) machine learning, patented Voice over Internet Protocol (“VoIP”), no-code development platform, and other powerful technologies.
• Infobird is also pioneering a new product that is differentiated from standard private domain traffic tools, allowing enterprises with a large customer base to cost-effectively personalize and automate their services

Infobird (NASDAQ: IFBD) has consistently innovated and offered unique customer-engagement solutions. The company has made a name for itself by leveraging proprietary next-generation technology, a product of years of research and development (“R&D”). This has allowed it to stamp its position as a leader in the Software-as-a-Service (“SaaS”) industry, particularly in the Chinese market. Infobird has been known to help companies manage the complete customer journey, starting from pre-sales activities to post-sale customer support. All this has ridden on the backbone of a self-developed, cloud-computing structure, robotic-process-automation (“RPA”) machine learning, patented Voice over Internet Protocol (“VoIP”), no-code development platform and many other such technologies (https://ibn.fm/uF6Th). Incremental improvements and developments over the years have rendered Infobird a pioneer in the industry and a trailblazer in what its technology can do from a customer relationship management (“CRM”) standpoint. Infobird is one of the very few companies in China to have built, from scratch, a customer engagement SaaS on a cloud-native architecture. A resource-intensive project in its development translates to cost-savings for clients who can scale their operations affordably and effectively without sacrificing on security or stability. This, in addition to Infobird’s no-code development, place it in a league of its own while also offering it an opportunity to further develop new SaaS with pre-programmed microservices at a significantly low cost and with quick reactions to new market opportunities. It is projected that the CRM market will be valued at $96.39 billion by 2027, up from $41.93 billion in 2019. Infobird plans to capitalize on this growth and play a central role in the industry’s growth. Recent client acquisitions such as SaSa, a Hong Kong beauty retailer, Zu Li Jian, a leading footwear brand in China, and a top fintech enterprise in China are all strong indications of a company positioning itself for the growth to come. Infobird is also pioneering a new product that is differentiated from standard private domain traffic tools. It is achieving this through the integration of RPA analysis and Artificial Intelligence (“AI”), thereby allowing enterprises with a large customer base to personalize and automate their services while reducing their operational costs and improving efficiency. Infobird’s customer-engagement solutions are unlike any other in the market today. The company is constantly pushing the envelope with innovation and technology, further reinforcing its title as a company of firsts and also as the undisputed industry leader. For more information, visit the company’s website at www.Infobird.com/en/index. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• FingerMotion’s focus has been on Sapientus, a major milestone for the company; delivering data-enabled insurance solutions that employ behavioral insights to change the existing service options
• Sapientus uses algorithms that supply insurers with actionable intel and facilitate efficient and effective delivery while increasing the ability to calculate risk and create more innovative products
• The company’s Nasdaq application has been submitted; FingerMotion has brought in third-party advisors to assist legal counsel in responding in a timely manner to any examiner questions
• SEC filings show that FingerMotion has allocated research and development funding to rich communications services, and it is expected that the company will be tapping into that industry’s growth potential

In a recent corporate update call (https://ibn.fm/BHbi7), tech company FingerMotion (OTCQX: FNGR) has shown increasing trends, especially in reports filed with the SEC. As an evolving technological company with core competencies in SMS/MMS services, mobile payment and recharge solutions, and big data insights, these trends support the company’s increasing focus on research and development, bolstering the commitment to developing high-demand applications for both consumers and businesses. Most of FingerMotion’s expenditures during 2021 have been a result of its youngest operational division, Sapientus. Sapientus represents a major milestone for the company. The division allows for the delivery of data-enabled insurance solutions employing behavioral insights to augment existing service options. The service offerings increase the insurers’ ability to calculate risk and create more innovative products. Sapientus uses advanced algorithms that supply more actionable intel and facilitate efficient and effective delivery. All available data is integrated to create proprietary risk matrices, which are then used in the final product offering. Sapientus has generated $33,077 in revenue during Q4 2021 and $98,715 in Q1 2022, and the quarter-over-quarter increase clearly shows the division’s growing success (https://ibn.fm/9AHXL). “In the past few years, we’ve had our inhouse team of actuaries and data scientists, who really know the ins and outs of the insurance industry, and what they’ve been doing is they’ve been deciphering information from all these different sources and putting them in the risk metrics that could provide those fresh insights and intelligence for the insurance field,” CEO Martin Shen said in the August corporate update (https://ibn.fm/BgOPy). The company’s current Nasdaq application was also discussed in the corporate update. An initial application for the Nasdaq listing has been submitted, and the first examiner letter has been received. FingerMotion has since hired private advisors and, with the assistance of its legal counsel, responded quickly to the examiner’s initial letter. While the process is well on its way to potential approval, FingerMotion acknowledges there is still a substantial amount of ground to cover before approval is granted. The company is remaining optimistic but realistic in the endeavor. In the August update, Mr. Shen shared a three-stage development strategy for FingerMotion:

• Stage 1
  • Partner with reinsurers
  • Revenue Sources: fees-for-services
• Stage 2
  • Expand analytics and risk metrics
  • Revenue Sources: fees-for-services; commissions; profit shares
• Stage 3
  • Integrate partners’ business into FingerMotion’s ecosystem
  • Revenue Sources: fees-for-services; commissions; profit shares

FingerMotion’s additional focus is also on the research and development of rich communications services (“RCS”). RCS is an emerging technology that revolutionizes text-based messaging by eliminating constraints commonly associated with short text messaging. Extended capabilities of RCS include file sharing, video calling, group chat, and more native services without the use of third-party applications. As a market, RCS is expected to grow from $5.2 billion in 2020 to $11.7 billion by 2025, registering a CAGR of 17.6% during the forecast period (https://ibn.fm/aRbDm). Having already allocated research and development funding to this sector (per SEC filings), FingerMotion is poised to tap into this particular growth opportunity with a dedicated RCS division. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• MONI contributing to closing gender gap in tech with all-female advisory board
• MONI’s women-led advisory board comprises industry leaders with decades of experience in finance, technology, media, and marketing
• MONI capitalizing on fintech rapid growth with proprietary applications under development designed to revolutionize how people gift and purchase cryptocurrency

Organizations worldwide are banding together to help close the gender gap in technology through programs that advocate policy changes, strategic public-private partnerships, educational programs, fundraising, and scholarships. Moon Equity Holdings (OTC: MONI), an investment company concentrating on acquisitions in real estate, precious metals, and cryptocurrency, aims to contribute to raising the ranks of women in fintech. Alison Galardi, CEO, resides at the helm of MONI and works alongside a women-led advisory board comprised of industry leaders with decades of experience in finance, technology, media, and marketing. “Since the emerging crypto space is mostly male dominated, we set out to align our team with a diverse group of senior females in technology and banking,” Galardi said. Sue Ferrari, a Senior Industry Principal with over 20 years of experience, brings expertise in technology, financial services, and media from previous roles that included Vice President of Bank of NY Mellon and ADP. Maureen Vizvary brings product development and marketing experience from previous positions at HP and Xerox, including a role at Microsoft where she restructured the company’s mid-market sales division and developed award-winning innovative technology that transformed how hospitals interact with patient data. Rounding out the team is Colleen Cline, who brings over 33 years of award-winning expertise from roles in the financial services and insurance industries that include sales, marketing, business development, and management positions. “We have to get more women in the industry,” said Anthony Scaramucci, founder of SkyBridge Capital, in a recent interview where he discussed current finance and crypto news (https://ibn.fm/ejN8i). “The more diverse we are, the smarter we are. We can draw on people from all over the place,” he concluded. Industry leaders worldwide share Scaramucci’s opinion that an increase in women would benefit the fintech space. Among them is Caroline Bowler, CEO of BTC Markets in Melbourne, Australia’s largest digital asset exchange. “There are lots of entry points into cryptocurrency and into blockchain businesses and you don’t have to be a developer or specializing in blockchain in order to find your place within this ecosystem,” said Bowler in a recent article. Citing cryptocurrency’s notorious “bro” culture and Australia’s perceived checkered record on gender equity, Bowler believes the industry continues to be male-dominated. However, she is hopeful that conditions will change as more women enter the sector. “As crypto becomes increasingly mainstream and more women come in, the impact of that ‘crypto bro’ is diluted and the normal mainstream acceptance comes through,” she concluded. Moon Equity Holdings, a pioneer within the global fintech sector, is capitalizing on the rapid growth in fintech with proprietary applications under development designed to revolutionize how people gift and purchase cryptocurrency. Along with seeking to make an impact on technology, MONI plans to leverage its diverse management team – including its all-female advisory board – to create unique solutions that appeal to a wide range of markets in an effort to enhance the customer experience, create a loyal following, and generate repeat business. For more information, visit the company’s website at www.MoonEquityHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to MONI are available in the company’s newsroom at https://ibn.fm/MONI

• Tryp Therapeutics has partnered with Dr. Paul Hutson and Dr. Christopher Nicholas, researchers at the University of Wisconsin-Madison
• The collaboration will focus on a clinical pharmacology studies to evaluate the safety and pharmacokinetics of TRP-8803, Tryp’s proprietary drug formulation
• The partnership is the latest in a series of collaborations as the company prepares for Phase 2b trials
• Tryp intends to use data from its Phase 2a clinical studies, expected to launch this year, coupled with preclinical data and clinical pharmacology data for TRP-8803, to support the use of the novel drug formulation in Phase 2b trials

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a company leading the next wave of psychedelics beyond mental health and unleashing the full potential of psilocybin for conditions with unmet needs, recently announced a collaboration with researchers at the University of Wisconsin-Madison, as part of preparations toward the planned Phase 2b studies (https://ibn.fm/Rt60z). Under the partnership, Dr. Paul Hutson, PharmD, a Professor of the Pharmacy Practice Division at the University of Wisconsin-Madison School of Pharmacy, and Dr. Christopher Nicholas, PhD, an Assistant Professor at the University of Wisconsin-Madison School of Medicine and Public Health, will support clinical pharmacology studies for TRP-8803, Tryp’s proprietary drug formulation with a novel route of administration. Once completed, the studies will provide additional regulatory support for TRP-8803. The pair will also serve as investigators on a clinical pharmacology study to evaluate the safety and pharmacokinetics of TRP-8803 in healthy, volunteer patients. Dr. Hutson, who has been the Principal Investigator for a safety and dose-escalation clinical trial for psilocybin performed at the university, brings a wealth of experience assessing the therapeutic uses of psilocybin and other psychoactive medications. Similarly, Dr. Nicholas, a trained clinical psychologist and neuroscientist with expertise in psychedelic-assisted therapy, brings extensive clinical trial-related experience, having served as the Principal Investigator on several psilocybin clinical trials and mechanistic studies. As Tryp’s partner, he will offer guidance on study design, behavioral and biological outcome measures, and psychological support to ensure participants will successfully complete the pharmacology study. This partnership is the latest in a series of collaborations with scholars, institutions, and companies, as Tryp prepares for its Phase 2b clinical studies. In July, Tryp announced an agreement with the University of Michigan as part of upcoming bridging studies designed to grow its IP portfolio for TRP-8803 and facilitate the drug formulation’s advancement into Phase 2b trials (https://ibn.fm/4ZRPx). Later, in August, Tryp announced partnerships with Calvert Labs – an Altasciences company – and Gad Consulting Services. Under the terms of the agreement, Calvert Labs will design and execute exploratory bridging studies to generate toxicology and blood exposure level data for TRP-8803, while Gad Consulting will advise on specific aspects of these studies. Tryp will then work with Altasciences to perform clinical pharmacology studies in healthy, volunteer patients (https://ibn.fm/vTGTr). The latest collaboration with researchers from the University of Wisconsin-Madison, therefore builds on the diligence that Tryp is completing through the Altasciences partnership on clinical pharmacology studies. Tryp has also made substantial strides toward the expected launch of the Phase 2a clinical studies to evaluate TRP-8802, a non-proprietary oral formulation of synthetic psilocybin. The company recently achieved its most important milestone yet when it submitted to the FDA an Investigational New Drug (“IND”) application to evaluate the oral formulation (https://ibn.fm/0rkQL). Using TRP-8802 for its Phase 2a studies allows the company to quickly initiate its clinical trials as it determines the effectiveness of psilocybin for its target indications, which include eating disorders such as binge eating disorder and hypothalamic obesity, and chronic pain disorders such as fibromyalgia, phantom limb pain, and CRPS. Tryp intends to use the data generated through the Phase 2a studies, combined with preclinical data for TRP-8803 and clinical pharmacology data from studies – including those supported by Dr. Hutson and Dr. Nicholas – to back the use of TRP-8803 in Phase 2b trials and beyond as well as in eventual commercialization (https://ibn.fm/vZkzp). For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF